
Soligenix's Behçet's Disease Therapy Receives UK Regulatory Innovation Designation
Soligenix's investigational therapy SGX945 received Promising Innovative Medicine designation from the UK's MHRA for treating Behçet's disease, signaling regulatory confidence in its potential to address this rare condition with limited treatment options.
Read full story
























